Effects of the probiotic Bifidobacterium animalis subsp. lactis on the non-surgical treatment of periodontitis. A histomorphometric, microtomographic and immunohistochemical study in rats
- 2017-06-29
- PLOS ONE 12(6)
- M. S. Ricoldi
- F. Furlaneto
- L. Oliveira
- G. C. Teixeira
- Jéssica P Pischiotini
- A. L. Moreira
- E. Ervolino
- M. N. de Oliveira
- C. Bogsan
- S. Salvador
- M. Messora
- PubMed: 28662142
- DOI: 10.1371/journal.pone.0179946
Abstract
Lactobacillus probiotics have been investigated in periodontitis. However, the effects of the genus Bifidobacterium on periodontitis are hardly known. This study evaluated the effects of the probiotic (PROB) Bifidobacterium animalis subsp. lactis (B. lactis) HN019 as an adjunct to scaling and root planing (SRP) in rats with experimental periodontitis (EP). At baseline, 32 rats were assigned to 4 groups: C (control), PROB, EP-SRP and EP-SRP-PROB. In groups EP-SRP and EP-SRP-PROB, the mandibular first molars of the animals received a ligature. At day 14, the ligatures were removed and SRP was performed. Animals of groups PROB and EP-SRP-PROB were orally administered with 10 mL/day of 109 colony forming units of B. lactis HN019 for 15 days, starting at day 14. Animals were euthanized at day 29. Histomorphometric, microtomographic and immunohistochemical analyses were performed. Microbiological effects of B. lactis on biofilm were also evaluated. Data were statistically analyzed (ANOVA, Tukey; Kruskal-Wallis, Dunn's; Two-tailed t-test; p<0.05). Group EP-SRP-PROB presented reduced alveolar bone resorption and attachment loss when compared with Group EP-SRP (p<0.05). Group EP-SRP-PROB showed significantly fewer osteoclasts, increased expression of anti-inflammatory cytokines and reduced expression of proinflammatory cytokines compared with Group EP-SRP (p<0.05). B. lactis promoted a higher ratio between aerobic and anaerobic bacteria in biofilm samples (p<0.05). B. lactis HN019 may have a role in the treatment of EP in rats, as an adjunct to SRP.
Research Insights
| Supplement | Health Outcome | Effect Type | Effect Size |
|---|---|---|---|
| Bifidobacterium animalis subsp. lactis | Improved Aerobic to Anaerobic Bacteria Ratio | Beneficial | Moderate |
| Bifidobacterium animalis subsp. lactis | Increased Anti-Inflammatory Cytokine Levels | Beneficial | Large |
| Bifidobacterium animalis subsp. lactis | Reduced Alveolar Bone Resorption | Beneficial | Moderate |
| Bifidobacterium animalis subsp. lactis | Reduced Attachment Loss | Beneficial | Moderate |
| Bifidobacterium animalis subsp. lactis | Reduced Osteoclast Number | Beneficial | Moderate |
| Bifidobacterium animalis subsp. lactis | Reduced Proinflammatory Cytokine Expression | Beneficial | Large |
| Bifidobacterium animalis subsp. lactis BS-01 | Altered Gut Microbiome Composition | Beneficial | Moderate |
| Bifidobacterium animalis subsp. lactis BS-01 | Increased Anti-Inflammatory Cytokine Expression | Beneficial | Moderate |
| Bifidobacterium animalis subsp. lactis BS-01 | Reduced Alveolar Bone Resorption | Beneficial | Moderate |
| Bifidobacterium animalis subsp. lactis BS-01 | Reduced Attachment Loss | Beneficial | Moderate |
| Bifidobacterium animalis subsp. lactis BS-01 | Reduced Osteoclast Activity | Beneficial | Large |
| Bifidobacterium animalis subsp. lactis BS-01 | Reduced Pro-inflammatory Cytokine Levels | Beneficial | Moderate |
| Bifidobacterium animalis subsp. lactis HN019 | Improved Aerobic to Anaerobic Bacteria Ratio | Beneficial | Moderate |
| Bifidobacterium animalis subsp. lactis HN019 | Increased Anti-Inflammatory Cytokine Levels | Beneficial | Large |
| Bifidobacterium animalis subsp. lactis HN019 | Reduced Alveolar Bone Resorption | Beneficial | Moderate |
| Bifidobacterium animalis subsp. lactis HN019 | Reduced Attachment Loss | Beneficial | Moderate |
| Bifidobacterium animalis subsp. lactis HN019 | Reduced Osteoclast Number | Beneficial | Moderate |
| Bifidobacterium animalis subsp. lactis HN019 | Reduced Proinflammatory Cytokine Expression | Beneficial | Large |
| Bifidobacterium animalis subsp. lactis LAFTI B94 | Increased Anti-Inflammatory Cytokine Levels | Beneficial | Large |
| Bifidobacterium animalis subsp. lactis LAFTI B94 | Increased Ratio of Aerobic to Anaerobic Bacteria in Biofilm | Beneficial | Moderate |
| Bifidobacterium animalis subsp. lactis LAFTI B94 | Reduced Alveolar Bone Resorption | Beneficial | Moderate |
| Bifidobacterium animalis subsp. lactis LAFTI B94 | Reduced Attachment Loss | Beneficial | Moderate |
| Bifidobacterium animalis subsp. lactis LAFTI B94 | Reduced Osteoclast Number | Beneficial | Moderate |
| Bifidobacterium animalis subsp. lactis LAFTI B94 | Reduced Pro-inflammatory Cytokine Levels | Beneficial | Moderate |
| Bifidobacterium lactis BS01 | Increased Anti-Inflammatory Cytokine Levels | Beneficial | Large |
| Bifidobacterium lactis BS01 | Reduced Alveolar Bone Resorption | Beneficial | Moderate |
| Bifidobacterium lactis BS01 | Reduced Attachment Loss | Beneficial | Moderate |
| Bifidobacterium lactis BS01 | Reduced Osteoclast Number | Beneficial | Moderate |
| Bifidobacterium lactis BS01 | Reduced Proinflammatory Cytokine Expression | Beneficial | Large |
| Bifidobacterium lactis HN019 | Improved Aerobic to Anaerobic Bacteria Ratio | Beneficial | Moderate |
| Bifidobacterium lactis HN019 | Increased Anti-Inflammatory Cytokine Levels | Beneficial | Large |
| Bifidobacterium lactis HN019 | Reduced Alveolar Bone Resorption | Beneficial | Moderate |
| Bifidobacterium lactis HN019 | Reduced Attachment Loss | Beneficial | Moderate |
| Bifidobacterium lactis HN019 | Reduced Osteoclast Number | Beneficial | Moderate |
| Bifidobacterium lactis HN019 | Reduced Proinflammatory Cytokine Expression | Beneficial | Large |
| Bifidobacterium lactis MAK16B42L | Increased Anti-Inflammatory Cytokine Levels | Beneficial | Large |
| Bifidobacterium lactis MAK16B42L | Reduced Alveolar Bone Resorption | Beneficial | Moderate |
| Bifidobacterium lactis MAK16B42L | Reduced Attachment Loss | Beneficial | Moderate |
| Bifidobacterium lactis MAK16B42L | Reduced Osteoclast Number | Beneficial | Moderate |
| Bifidobacterium lactis MAK16B42L | Reduced Proinflammatory Cytokine Expression | Beneficial | Large |